IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Lonza and Human Genome Sciences Sign Manufacturing Agreement

11:55 PM MDT | July 12, 2010 | Deepti Ramesh

Lonza says it has entered into an agreement with Human Genome Sciences (HGS; Rockville, MD) for the future commercial supply of Benlysta (belimumab), which is currently under regulatory review in the U.S. and Europe as a potential new treatment for systemic lupus erythematosus (SLE). Benlysta is being developed by HGS and GlaxoSmithKline (GSK; London) under a co-development and commercialization agreement entered into in 2006. GSK submitted a marketing authorization application last month to the European Medicines Agency, seeking approval to market belimumab in...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa